TrialResults - center   -  Clinical trials results database in


Clinical trials of Hirulog-1 Hirulog Angiomax (bivalirudin)     pdf     short list

Clinical trials of Hirulog-1 Hirulog Angiomax (bivalirudin) and meta-analysis are available for the following clinical conditions:


percutaneous coronary intervention

These trials are included in meta-analysis concerning: antithrombotics in all type of patients, anticoagulant in all type of patients,

bivalirudin vs heparin + GP2b3a inhibitors
REPLACE-2 ,2003 bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI
versus
heparin plus planned Gp IIb/IIIa blockade
patients undergoing urgent or elective PCI 30 days
double blind
9 countries
HORIZONS-AMI (Stone) ,2008
NCT00433966
Bivalirudin
versus
Heparin plus GP IIb/IIIa inhibitor
patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI 30 days
open
11 countries
ACUITY (sub groups, bivalirudin alone) ,2007 bivalirudin alone
versus
heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors
patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography. 30 days
open
ACUITY (Stone) (bivalirudin alone) ,2006
NCT00093158
bivalirudin alone
versus
unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor
patients with acute coronary syndromes 30 days
open
Kleiman ,2002 bivalirudin + eptifibatide
versus
heparin + eptifibatide
patients who underwent elective percutaneous coronary intervention
open
ACUITY (sub groups, bivalirudin +aGP2b3a) ,2007 bivalirudin +
versus
heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors
patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography. 30 days
open
bivalirudin vs LMWH
CACHET (without abciximab) ,2002 bivalirudin without abciximab
versus
low-dose weight-adjusted heparin with abciximab
patients who underwent coronary intervention 7 days or hospital discharge
open
bivalirudin vs no control
Topol ,1993 five different dosages of bivalirudin (a bolus dose of 0.15-0.55 mg/kg followed by a continuous infusion dosage of 0.6-2.2 mg/kg/hour for 4 hours)
versus
no control group


bivalirudin vs UFH
ISAR-REACT 3 ,2008
NCT00262054
UFH bolus of 140 U/kg
versus
bivalirudin (bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg/hr)
troponin-negative patients undergoing PCI 30 days (mean)
double blind
REPLACE-1 ,2004 bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion during the procedure
versus
heparin (70 U/kg initial bolus) adjusted to ACT of 200 to 300s
patients undergoing elective or urgent revascularization hospital stay (48h min)

US
BAT (Bittl) ,1995 bivalirudin immediately before angioplasty.
versus
heparin immediately before angioplasty
patients undergoing urgent angioplasty for unstable or postinfarction angina hospital stay
double blind
US
ARMYDA BIVALVE bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg per hour during the procedure)
versus
unfractionated heparin (75 IU/kg)
patients at high bleeding risk (over 75 years of age, diabetes, reduced renal function) scheduled for PCI

bivalirudin vs UFH plus tirofiban
NAPLES (Tavano) ,2009 bivalirudin monotherapy
versus
unfractionated heparin plus tirofiban
patients with diabetes mellitus undergoing elective percutaneous coronary intervention 30 days
open
Italy
Prasugrel and Bivalirudin vs Clopidogrel and Heparin
BRAVE-4 (ongoing)
NCT00976092
Prasugrel + Bivalirudin
versus
Clopidogrel + Heparin
STEMI patients undergoing PPCI

acute coronary syndrome

These trials are included in meta-analysis concerning: antithrombotics in all type of patient, antithrombotics in PCI sub group, antithrombotics in patients managed with an early invasive strategy,

bivalirudin vs heparin + GP2b3a inhibitors
ACUITY (biva alone vs hep+aGP2b3a) ,2006
NCT00093158
bivalirudin alone
versus
unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor
in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. 30 days
double blind
17 countries worldwide
ACUITY (biva+aGP2b3a vs hep+aGP2b3a) ,2006
NCT00093158
bivalirudin plus a glycoprotein IIb/IIIa inhibitor
versus
unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor
in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. 30 days
double blind
17 countries worldwide
bivalirudin vs eptifibatide + heparin
PROTECT-TIMI 30 ,2006
NCT00250471
bivalirudin alone
versus
eptifibatide plus either unfractionated heparin or enoxaparin
non ST elevation ACS patients undergoing PCI hospital stay
open
International
bivalirudin vs heparin
HERO ,1997 Bivalirudin 0.125–0.250 mg/kg bolus; 0.125–0.500 mg /kg/min infusion for 72h
versus
UFH 5000 IU bolus; 1000–1200 IU/h infusion
AMI (patients presenting within 12 hours with ST-segment elevation) 35 days
double blind
BAT (Bittl) ,1995 Bivalirudin 1.0 mg/kg bolus; 2.5 mg /kg/h for 4 h, then 0.2 mg /kg/h infusion for 24h
versus
UFH 175 IU/kg bolus; 15 IU mg /kg/h infusion
patients undergoing angioplasty for unstable or postinfarction angina 6 months
double blind
North America and Europe
bivalirudin + GP2b3a inhibitors vs heparin + GP2b3a inhibitors
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé ,2007 bivalirudin +
versus
heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors
patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography. 30 days
open
ACUITY (sub groups PCI, bivalirudin alone) importé ,2007 bivalirudin alone
versus
heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors
patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography (sub group). 30 days
open

acute myocardial infarction

These trials are included in meta-analysis concerning: antithrombotics in all type of patients, anticoagulant in all type of patients,

Horizons ,2008
NCT00433966
bivalirudin
versus
heparin plus a GP IIb/IIIa inhibitor
STEMI patients within 12 hours of symptom onset who were undergoing primary PCI
open
bivalirudin vs heparin
HERO ,1997 Bivalirudin 0.125–0.250 mg/kg bolus; 0.125–0.500 mg /kg/min infusion for 72h
versus
UFH 5000 IU bolus; 1000–1200 IU/h infusion
AMI (patients presenting within 12 hours with ST-segment elevation) 35 days
double blind

post myocardial infarction

These trials are included in meta-analysis concerning: anticoagulant in all type of patients,

Horizons ,2008
NCT00433966
bivalirudin
versus
heparin plus a GP IIb/IIIa inhibitor
STEMI patients within 12 hours of symptom onset who were undergoing primary PCI
open



Entry terms: Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, bivalirudin, Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64), Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen, Hirulog-1, Hirulog, Angiomax, The Medicines Company brand of bivalirudin, BG 8967, BG8967, BG-8967



Search Hirulog-1 Hirulog Angiomax clinical trials in Pubmed

Search Hirulog-1 Hirulog Angiomax clinical trials in ClinicalTrials.gov

Search Hirulog-1 Hirulog Angiomax clinical trials in Wikipedia

Search Hirulog-1 Hirulog Angiomax in drugs.com




browse_trt3b

 
(c) 2006-2014TrialResults-center - All rights reserved Sitemap | Feedback | Disclaimer & Privacy Policy | Copyright | Home | Top
Last uptaded on 2014/11
63 user(s) connected

Creative Commons License TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .


OpenSearch feed - Add TrialResults-center.org to your browser's search bar